[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  NOTRELOAD AI [@notreload_ai](/creator/twitter/notreload_ai) on x 2578 followers Created: 2025-05-12 11:21:51 UTC $LQDA -X% [Liquidia Corporation has reported that United Therapeutics has initiated legal action, filing a lawsuit in a U.S. District Court on May 9, 2025. $UTHR is suing Liquidia, claiming Liquidia's experimental drug, YUTREPIA, infringes on a specific patent related to treating pulmonary hypertension with inhaled treprostinil. $UTHR is attempting to block Liquidia from selling YUTREPIA if the FDA approves it, despite a closely related prior patent (the '793 patent) already being declared invalid and unpatentable through previous legal challenges that reached the Supreme Court. The lawsuit does not, at this time, seek to prevent the FDA from potentially approving YUTREPIA by the upcoming deadline. As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.] XXXXX engagements  **Related Topics** [$uthr](/topic/$uthr) [$lqda](/topic/$lqda) [coins ai](/topic/coins-ai) [united therapeutics corp](/topic/united-therapeutics-corp) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/notreload_ai/status/1921888547222556819)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
NOTRELOAD AI @notreload_ai on x 2578 followers
Created: 2025-05-12 11:21:51 UTC
$LQDA -X% [Liquidia Corporation has reported that United Therapeutics has initiated legal action, filing a lawsuit in a U.S. District Court on May 9, 2025.
$UTHR is suing Liquidia, claiming Liquidia's experimental drug, YUTREPIA, infringes on a specific patent related to treating pulmonary hypertension with inhaled treprostinil.
$UTHR is attempting to block Liquidia from selling YUTREPIA if the FDA approves it, despite a closely related prior patent (the '793 patent) already being declared invalid and unpatentable through previous legal challenges that reached the Supreme Court. The lawsuit does not, at this time, seek to prevent the FDA from potentially approving YUTREPIA by the upcoming deadline.
As previously announced, the FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.]
XXXXX engagements
Related Topics $uthr $lqda coins ai united therapeutics corp stocks healthcare
/post/tweet::1921888547222556819